Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| Evolus, Inc.EOLS · Entity 5341 | Director | January 27, 2023 | February 01, 2023 |
| RESMED INCRMD · Entity 2692 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 86,452 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 86,452 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
Evolus, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,174 |
Reported balance
After 2023-01-27 transaction · row 1
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 8,293 · Balance 43,174 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.25 · Expires 2033-01-27 | Direct | 11,789 |
Reported balance
After 2023-01-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-27 · Grant · Acquired 11,789 · Balance 11,789 F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,000 |
Reported balance
Holding disclosure · report date 2023-01-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer
F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
RESMED INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 51,803 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 970 · Balance 51,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date May 03, 2018 · Filed May 07, 2018
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 36,713 |
Last balance in matching sequence
After 2018-05-03 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-05-03 · Exercise / conversion · Acquired 16,844 · Balance 35,490 F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-05-03 · Exercise / conversion · Acquired 6,000 · Balance 41,490 F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 3 · 2018-05-03 · Tax withholding · Disposed 4,777 · Balance 36,713 F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-03 · Exercise / conversion · Disposed 3,725 · Balance 0 F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-03 · Exercise / conversion · Disposed 2,501 · Balance 0 F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-03 · Exercise / conversion · Disposed 2,822 · Balance 0 F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-03 · Exercise / conversion · Disposed 2,130 · Balance 0 F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2018-05-22 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-03 · Exercise / conversion · Disposed 6,000 · Balance 0 F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired.
F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise.
F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested.
F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested.
F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested.
F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested.
F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested.
F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested.
F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2021 Filed Nov 23, 2021 00:45 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 1,695 | $0.00 Strike: $263.16 | $0.00 |
DisclosureSEC source: 0000943819-21-000037 · primary_doc.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695 Underlying: ResMed Common Stock · 1,695 shares Expires 2028-11-18 F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 00:45 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-21-000037 · primary_doc.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,102 F1 · balance_after: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2022, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 19:03 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 342 | $259.47 | $88,738.74 |
DisclosureSEC source: 0001127602-21-029094 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,624 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted 11/19/2020. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 22:39 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 36,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023942 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,966 F1 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:30 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001193805-21-000925 · e620745_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 22:12 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 19,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-21-000036 · wf-form4_161290873618832.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,313 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 5, 2021, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:00 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029753 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,636 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 11, 2020 Filed Nov 14, 2020 00:01 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 579 | $212.11 | $122,811.69 |
DisclosureSEC source: 0001127602-20-029031 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,449 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $40.70 | $0.00 |
DisclosureSEC source: 0001193805-20-000742 · e619721_4-farrell.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| January 23, 2020 Filed Jan 25, 2020 02:06 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 23,458 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001570562-20-000035 · wf-form4_157991798760151.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,458 Underlying: Common Stock · 23,458 shares Expires 2030-01-23 F1 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 23, 2020, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 20:26 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 1,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033667 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,028 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2020, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:07 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026109 · doc4.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-24 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 23:51 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 4,432 | $10.85 | $48,087.20 |
DisclosureSEC source: 0000899243-19-022258 · doc4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 42,955 F2 · price: The price reported in Column 4 is a weighted average price. 4,100 shares were purchased at a price of $10.86 per share and 332 shares were purchased at a price of $10.72 per share. F1 · ownership.nature: By Peter C. Farrell Trust. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 23:51 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 4,681 | $11.02 | $51,584.62 |
DisclosureSEC source: 0000899243-19-022258 · doc4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 38,523 F1 · ownership.nature: By Peter C. Farrell Trust. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:30 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock · Derivative | 26,163 | $0.00 Strike: $15.99 | $0.00 |
DisclosureSEC source: 0001570562-19-000113 · wf-form4_156339544054218.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,163 Underlying: Common Stock · 26,163 shares Expires 2029-07-15 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of two years, with 1/2 of the shares subject to the option vesting annually on the anniversary of July 15, 2019. Read SEC document |
| December 13, 2018 Filed Dec 13, 2018 23:20 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 13,866 | $115.40 | $1,600,067.07 |
DisclosureSEC source: 0001567619-18-007954 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,301 F1 · kind: Represents a gift of shares to Bank of America, N.A. Successor Trustee of Peter C. Farrell Charitable Remainder Unitrust. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 01:08 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 11,442 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0001567619-18-006569 · doc1.xml · derivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,442 Underlying: ResMed Common Stock · 11,442 shares Expires 2025-11-14 F2 · derivative.exercise_date: Options vest in full (i) on the first Nov. 11 following the grant date or (ii) the first annual shareholders meeting following grant date. Read SEC document |
| November 09, 2018 Filed Nov 17, 2018 01:08 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 729 | $106.94 | $77,959.26 |
DisclosureSEC source: 0001567619-18-006569 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,167 F1 · shares: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2017. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $39.45 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 10 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2018-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 9 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. F9 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,822 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 8 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,822 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. F8 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,501 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 7 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,501 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. F7 · derivative.expiration_date: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 3,725 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 6 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. F6 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. F5 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 2,833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 4,777 | $49.54 | $236,652.58 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 36,713 F3 · shares: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 6,000 | $39.45 | $236,700.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 41,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:59 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 16,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028409 · doc4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 35,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired. F2 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Read SEC document |
| December 18, 2017 Filed Dec 18, 2017 21:30 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 3,351 | $86.00 | $288,186.00 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,896 F2 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 15, 2017 Filed Dec 18, 2017 21:30 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 1,180 | $84.97 | $100,264.60 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,427 F3 · kind: Represents a gift of shares to Project Veritas. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:30 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 23,689 | $84.43 | $2,000,062.27 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,607 F2 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:30 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 23,689 | $84.43 | $2,000,062.27 |
DisclosureSEC source: 0001140361-17-046520 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,296 F1 · kind: Represents a gift of shares to the Farrell Family Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| November 28, 2017 Filed Nov 29, 2017 22:16 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,948 | $84.80 | $249,990.40 |
DisclosureSEC source: 0001140361-17-044227 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,985 F1 · kind: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: The price reported above represents the average of the high and low trading price on the day of the transaction. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 02:04 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,991 | $84.98 | $254,175.18 |
DisclosureSEC source: 0001140361-17-043277 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,933 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 1,858 | $83.06 | $154,325.48 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 9 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,942 F5 · shares: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 82,460 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 13 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 82,460 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 3,625 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 12 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 3,625 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,492 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 11 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 20,492 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 11,815 | $0.00 Strike: $52.02 | $0.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · derivative · entry 10 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 11,815 shares Expires 2021-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 82,460 | $82.70 | $6,819,442.00 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 8 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F4 · price: This transaction was executed in multiple trades at prices ranging from 82.49 to 82.89. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 3,625 | $82.69 | $299,751.25 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 7 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,260 F3 · price: This transaction was executed in multiple trades at prices ranging from $82.51 to $82.82. The price reported above reflects the weighted average sale price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,492 | $82.70 | $1,694,688.40 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 6 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,885 F2 · price: This transaction was executed in multiple trades at prices ranging from 82.53 to 82.87. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 11,815 | $82.71 | $977,218.65 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,377 F1 · price: This transaction was executed in multiple trades at prices ranging from 82.51 to 82.88. The price reported above represents the weighted average sales price. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 82,460 | $27.58 | $2,274,246.80 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 3,625 | $27.58 | $99,977.50 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,492 | $58.24 | $1,193,454.08 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 22:42 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 11,815 | $52.02 | $614,616.30 |
DisclosureSEC source: 0001140361-17-042207 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 2,000 | $83.82 | $167,634.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.76 to $83.93. The price reported above reflects the weighted average sale price. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 18,000 | $83.50 | $1,502,946.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 82.75 to 83.75. The price reported above represents the weighted average sales price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.